G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable
Prithviraj Bose,Aziz Nazha,Rami S. Komrokji,Keyur P. Patel,Sherry Pierce,Najla Alali,Andrew Sochacki,Aaron C. Shaver,Wencai Ma,Xiaoping Su,Naval Daver,Courtney D. DiNardo,Guillermo Garcia-Manero,Sanam Loghavi,Carlos E. Bueso-Ramos,Hagop M. Kantarjian,Mikkael A. Sekeres,Michael R. Savona,Jaroslaw P. Maciejewski,Srdan Verstovsek +19 more
TL;DR: The “unclassifiable” myelodysplastic/myeloproliferative neoplasms (MDS/MPN-U) remain the most poorly characterized among the various subtypes of MDS/ MPN.
Journal ArticleDOI
A Phase I and Pharmacodynamic Study of AT9283, a Small-Molecule Inhibitor of Aurora Kinases in Patients With Relapsed/Refractory Leukemia or Myelofibrosis
James M. Foran,Farhad Ravandi,William G. Wierda,Guillermo Garcia-Manero,Srdan Verstovsek,Tapan M. Kadia,Jan A. Burger,Murray Yule,Gillian Langford,John Lyons,John Ayrton,Victoria Lock,Gautham Borthakur,Jorge E. Cortes,Hagop M. Kantarjian +14 more
TL;DR: AT9283 tolerability was strongly dose-dependent, with reversible myelosuppression predominating at lower doses and events such as cardiovascular toxicities manifesting at higher doses.
Journal ArticleDOI
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia
Naveen Pemmaraju,Dhaval Shah,Hagop M. Kantarjian,Robert Z. Orlowski,Graciela M. Nogueras González,Veera Baladandayuthapani,Nitin Jain,Verena Wagner,Guillermo Garcia-Manero,Jatin P. Shah,Farhad Ravandi,Sherry Pierce,Koichi Takahashi,Naval Daver,Aziz Nazha,Srdan Verstovsek,Elias Jabbour,Marcos de Lima,Richard E. Champlin,Jorge E. Cortes,Muzaffar H. Qazilbash +20 more
TL;DR: The development of t-MN in patients with multiple myeloma is associated with poor outcomes, and these patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times.
Journal ArticleDOI
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
Ahmad S. Alotaibi,Musa Yilmaz,Rashmi Kanagal-Shamanna,Sanam Loghavi,Tapan M. Kadia,Courtney D. DiNardo,Gautam Borthakur,Marina Konopleva,Sherry Pierce,Sa A. Wang,Guilin Tang,Veronica A Guerra,Bachar Samra,Naveen Pemmaraju,Elias Jabbour,Nicholas J. Short,Ghayas C. Issa,Maro Ohanian,Guillermo Garcia-Manero,Kapil N. Bhalla,Keyur P. Patel,Koichi Takahashi,Michael Andreeff,Jorge E. Cortes,Hagop M. Kantarjian,Farhad Ravandi,Naval Daver +26 more
TL;DR: In this article, the authors studied pretreatment and relapse bone marrow samples from patients with FLT3-mutated AML treated with FLTs3i-based therapies (secondary resistance cohort), and pretreatment sample from patients who had no response to FLTs 3 inhibitors (primary resistance cohort) and identified emergent mutations involving on-target FLTs, epigenetic modifiers, RAS/MAPK pathway, and less frequently WT1 and TP53.
Journal ArticleDOI
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents
Ana Alfonso,Guillermo Montalban-Bravo,Koichi Takahashi,Elias Jabbour,Tapan M. Kadia,Farhad Ravandi,Jorge E. Cortes,Zeev Estrov,Gautam Borthakur,Naveen Pemmaraju,Marina Konopleva,Carlos E. Bueso-Ramos,BA Sherry Pierce Bsn,Hagop M. Kantarjian,Guillermo Garcia-Manero +14 more
TL;DR: HMA are effective in chronic myelomonocytic leukemia but new agents and combinations are needed, and this data could be a benchmark for further drug development in CMML.